Adverse events of targeted therapies reported by patients with cancer treated in primary care.

Background: Targeted Therapies (TT) are among the therapeutic innovations for cancer treatment in outpatient settings. TT-related Adverse Events (AEs) are a source of loss of opportunity for patients if their management is inappropriate.

Objectives: The objective of this study was to describe the AE frequency and severity as reported by patients with cancer who received TT in ambulatory settings.

[Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma].

Background: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). Due to its peculiar toxicities, improving patient's tolerance may need close follow-up. Nurses can play a crucial role, by driving a patient education program (EP).